At present, only one Nectin-4 ADC drug, Padcev (enfortumab vedotin), has been approved for marketing for the second-line treatment of patients with uroepithelial cancer.
Here, we will analyze the three FDA approved ADCs for the HER2-positive, HER2-low, and HER2-negative breast cancers.
According to the current trend, the total global ADC drug sales are expected to exceed $10 billion in 2023, which will become another important milestone in the ADC field. Below we present th…
Summary of targeted protein degradation, such as PROTAC and molecular glues in clinical trials.
We will summarize the anti-tumor drug targets that have been newly discovered or have new indications recently.
What are helper lipids? Whats the role of helper lipids in lipid nanoparticles?
ADCs are being actively investigated in preclinical and clinical trials in combination with other anticancer agents, including chemotherapy, molecularly targeted agents, and immunotherapy.
Enhertu (fam-Trastuzumab deruxtecan-nxki) is a HER2-targeting ADC drug jointly developed by AstraZeneca and Daiichi Sankyo, also known as DS-8201 or T-DXd.
So what are the new anti-cancer drugs approved in the first half of the year? As can be seen from the table below, the new drugs approved by the FDA in the first half of the year covered a v…
We provide an overview of the current landscape of oral peptides in marketing and clinical studies, a review of the forms of delivery used, and a summary and analysis of the common strategies…